Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

DMPK and Physical Sciences

The timely delivery and interpretation of discovery DMPK data is essential in the optimisation of key parameters such as Absorption, Distribution, Metabolism, Excretion (ADME) and Physico-Chemical properties during the Drug Discovery process.

A Fit-for-Purpose approach is usually taken that involves working with you to understand the molecular target and the required pharmacokinetics, benchmarking tool or lead molecules to understand their liabilities and opportunities for improvement as well as designing and adopting a flexible DMPK screening cascade to support your medicinal chemistry and bioscience efforts.

With a mission to deliver tailored DMPK expertise through innovation, quality and commitment, the DMPK and Physical Sciences team will utilise a large selection of validated in vitro assays and state-of-the-art analytical capabilities to support your requirement.

To ensure an efficient and rapid turnaround of key DMPK data in support of a design-make-test-analyse cycle in each project, and to ensure effective support through each stage of the Discovery process, we will provide the following:

  • Access to a DMPK project representative who will guide you (if required) through the discovery process from planning to data delivery. Any work placed with us will also have access to our DMPK scientific experts for consultancy input. An optional summary report that can be adapted to your own existing template or format can also be generated
  • Access to a comprehensive range of standard in vivo and in vitro service offerings which are offered at globally competitive prices


Our DMPK service offerings in support of Drug Discovery

What our DMPK service offers

Our state-of-the-art laboratory equipment

Our cutting edge and ultra-modern laboratories include the latest mass spectrometers such as the Xevo G2-XS QTOF Mass Spectrometer, designed for both routine qualitative and quantitative UPLC-MS/MS applications, allowing us to confidently identify parent and metabolites in both in vitro and in vivo biological samples.

Our equipment includes:

  • Waters Acquity I-Class UPLC systems
  • Agilent 1200 HPLC systems
  • Waters Xevo TQ-S Mass Spectrometers
  • Waters Xevo G2-XS QTOF High Resolution Mass Spectrometers
  • Sciex API5500 QTrap High Resolution Mass Spectrometers
  • Molecular devices 384 Spectrophotometer
  • Beckman Biomek® NXP, robotic sample prep workstations
  • Hidex Sense, scintillation counter
  • ImageXpress Micro Confocal High-Content Imaging System
  • MD SpectraMax 384, fluorescence detector
  • EnVision Multimode Plate Reader
  • 4°C Storage Units
  • -20°C Cold Storage Units
  • -80°C Ultra Cold Storage Units

Why work with us?

Our mission is to deliver tailored DMPK expertise through innovation, quality and commitment.

  • We provide expert guidance and problem-solving solutions. Our scientists don’t just deliver your data, but also apply in-depth analysis expert input to interpret your data, establish/amend DMPK screening cascades and/or scale the data to human.
  • We provide a comprehensive range of validated assays. Our assays include an extensive list of Physico-Chemical assays, in vitro ADME assays, in vitro Toxicology assays, in vivo pharmacokinetics and bioanalysis, as well as IVIVE, PK/PD and Human PK predictions.
  • We offer complete transparency. Throughout the course of your project, you will have direct access to our data via our state of the art Informatics infrastructure to facilitate discussions and decision making.
  • We offer both stand-alone Fee for Service (FFS) or Full-Time-Equivalent (FTE) business models to help you with your DMPK requirements


Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

DMPK and Physical Sciences Services

Physicochemical Profiling

It is well understood that poor physicochemical properties are associated with increased failure of drug candidates within the pre-clinical and clinical development process. Assessing these parameters during the discovery optimisation process is critical.


In Vitro ADME

The assessment of the Absorption, Distribution, Metabolism, and Excretion (ADME) properties of compounds is a critical component is supporting the development of compounds within Discovery and Development. 


In Vivo Pharmacokinetics

At Sygnature Discovery we offer services to support your non-GLP in vivo Pharmacokinetics studies in preclinical species including the planning of these studies and the analysis of any samples generated by UPLC-MS


PK and Bioanalysis

Sygnature Discovery offers a range of pharmacokinetics, bioanalysis and metabolite identification services adapted to each project needs. Our experience is complemented with a suite of state-of-the art bioanalytical and metabolic identification mass spectrometry equipment.


Metabolite Identification and Biotransformation

Sygnature Discovery offers a range of metabolite identification and biotransformation services adapted to each project needs. Our experience is complemented with a suite of state-of-the art mass spectrometry equipment.


IVIVE and Human PK Predictions

The DMPK team at Sygnature Discovery has several years of experience in PK modelling and simulation. In complement to our in vitro and in vivo ADME laboratory-based services, we also offer several IVIVE and PK prediction packages to support the various stages of the drug discovery process from screening, to selection and to election of a pre-clinical drug candidate.


DMPK Consultancy

Sygnature Discovery offers a range of DMPK consultancy services to drug discovery research teams within the academic, pharmaceutical, biotechnology, charity and CRO sectors as well as to life science venture capital funds.


Latest News

View All

Sygnature Discovery moves US base to Kendall…

Sygnature Discovery raises over £2,776 for Cancer…

Sygnature Discovery named as Finalist in 2019…

Hidden chemistry in flowers shown to kill…